Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Ryan

Showing results (121-130 of 274) with videos related to

Pageof 28
Sort By:
Journal of Gastrointestinal Cancer|April 14, 2019
Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal CancerDivya Yerramilli, Lorraine Drapek, Ryan D Nipp, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Cancer|January 30, 2002
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaDavid P Ryan, Matthew H Kulke, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Cancer|June 23, 2007
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Keith Stuart, Lawrence S Blaszkowsky, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityThomas A Puchalski, David P Ryan, Rocio Garcia-Carbonero, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case reportDouglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
The Oncologist|June 1, 2017
Predictors of Disruptions in Breast Cancer Care for Individuals with SchizophreniaKelly E Irwin, Elyse R Park, Jennifer A Shin, et al.
The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Pageof 28

Showing results (121-130 of 274) with videos related to

Sort By:
Pageof 28
Journal of Gastrointestinal Cancer|April 14, 2019
Sexual Function, Quality of Life, and Mood After Radiation Therapy in Patients with Anal CancerDivya Yerramilli, Lorraine Drapek, Ryan D Nipp, et al.
Cancer|October 13, 2006
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumorsDavid P Ryan, Leonard J Appleman, Thomas Lynch, et al.
Cancer|January 30, 2002
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaDavid P Ryan, Matthew H Kulke, Charles S Fuchs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerMatthew H Kulke, Lawrence S Blaszkowsky, David P Ryan, et al.
Cancer|June 23, 2007
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinomaAndrew X Zhu, Keith Stuart, Lawrence S Blaszkowsky, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2002
Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicityThomas A Puchalski, David P Ryan, Rocio Garcia-Carbonero, et al.
Journal of Gastrointestinal Oncology|January 24, 2022
Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case reportDouglas Rubinson, Brian M Wolpin, Ilana S Warsofsky, et al.
The Oncologist|June 1, 2017
Predictors of Disruptions in Breast Cancer Care for Individuals with SchizophreniaKelly E Irwin, Elyse R Park, Jennifer A Shin, et al.
The Journal of Clinical Investigation|October 12, 2011
Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancersHiromichi Ebi, Ryan B Corcoran, Anurag Singh, et al.
Investigational New Drugs|July 30, 2011
A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancerJason E Faris, Jamie Arnott, Hui Zheng, et al.
Pageof 28